.JPG?ad=18503&adview=true)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pathology [D. R. S., C. A. P., H. F. D.], Beth Israel Hospital and Harvard Medical School and the Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215; and the Monsanto Company [J. F.], St. Louis, Missouri 63167
We have previously reported that rodent tumor cell lines secrete a potent vascular permeability factor with a molecular weight of 34,000–42,000 (Senger et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Wash. DC), 219: 983–985, 1983). This tumor-secreted vascular permeability factor (VPF) causes a rapid and completely reversible increase in microvascular permeability in the species (guinea pig or rat) from which the tumors were derived without causing mast cell degranulation or endothelial cell damage or exciting an inflammatory cell infiltrate. This VPF may be responsible, at least in part, for the increased permeability which is commonly displayed by solid and ascites tumor vessels. We have now examined 7 human tumor cell lines and have determined that 5 of them also secrete this same VPF. Antibody raised to guinea pig line 10 VPF neutralized more than 90% of the vascular permeability-increasing activity secreted by these 5 human tumor lines. Furthermore, VPFs from both guinea pig and human tumor sources bound to and were eluted similarly from immobilized heparin and comigrated identically on sodium dodecyl sulfate-polyacrylamide gels. Finally, 2 tumorigenic (in nude mice) human cell lines were found to secrete at least 14-fold more VPF than their directly matched, nontumorigenic counterparts, suggesting that elevated expression of this permeability factor may correlate with neoplastic transformation. These data suggest that a broad spectrum of tumor cells from several species, including humans, secretes a highly conserved molecule that enhances local vascular permeability and that this function may be important for tumor growth.
1 This investigation was supported by USPHS Grants CA-28471 and CA-40624, awarded by the National Cancer Institute, Department of Health and Human Services, and by a grant from the Monsanto Company.
2 To whom reprint requests should be addressed, c/o Department of Pathology, Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02215.
Received 6/ 3/86. Revised 8/ 1/86. Accepted 8/ 4/86.
This article has been cited by other articles:
|
|
 |
|
  M. T. Holderfield and C. C.W. Hughes Crosstalk Between Vascular Endothelial Growth Factor, Notch, and Transforming Growth Factor-{beta} in Vascular Morphogenesis Circ. Res., March 28, 2008; 102(6): 637 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Becker, N. Rohwer, T. Funakoshi, T. Cramer, W. Bernhardt, A. Birsner, J. Folkman, and R. J. D'Amato 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor-1{alpha} and Suppresses Growth of Lesions in a Mouse Model of Endometriosis Am. J. Pathol., February 1, 2008; 172(2): 534 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text]
|
|
|
|
 |
|
 H. M.W. Verheul, H. Hammers, K. van Erp, Y. Wei, T. Sanni, B. Salumbides, D. Z. Qian, G. D. Yancopoulos, and R. Pili Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model Clin. Cancer Res., July 15, 2007; 13(14): 4201 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini and W.K. Rathmell Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 741s - 746s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sugaya, L. Fang, A. R. Cardones, T. Kakinuma, S. H. Jaber, A. Blauvelt, and S. T. Hwang Oncostatin M Enhances CCL21 Expression by Microvascular Endothelial Cells and Increases the Efficiency of Dendritic Cell Trafficking to Lymph Nodes J. Immunol., December 1, 2006; 177(11): 7665 - 7672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tikkanen, M. Hollmen, A. I. Nykanen, J. Wood, P. K. Koskinen, and K. B. Lemstrom Role of Platelet-derived Growth Factor and Vascular Endothelial Growth Factor in Obliterative Airway Disease Am. J. Respir. Crit. Care Med., November 15, 2006; 174(10): 1145 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Qin, H. Zeng, and D. Zhao Requirement of Protein Kinase D Tyrosine Phosphorylation for VEGF-A165-induced Angiogenesis through Its Interaction and Regulation of Phospholipase C{gamma} Phosphorylation J. Biol. Chem., October 27, 2006; 281(43): 32550 - 32558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Becker, R. D. Wright, R. Satchi-Fainaro, T. Funakoshi, J. Folkman, A. L. Kung, and R. J. D'Amato A Novel Noninvasive Model of Endometriosis for Monitoring the Efficacy of Antiangiogenic Therapy Am. J. Pathol., June 1, 2006; 168(6): 2074 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Heymach Antiangiogenic Therapy for Cancer: from the Bench to Bedside and Back Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 177 - 180. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Glass, S. J. Harper, and D. O. Bates The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo J. Physiol., April 1, 2006; 572(1): 243 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hossein Pourgholami, Z. Yan Cai, Y. Lu, L. Wang, and D. Lawson Morris Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice. Clin. Cancer Res., March 15, 2006; 12(6): 1928 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chang, G. L. Firestone, and L. F. Bjeldanes Inhibition of growth factor-induced Ras signaling in vascular endothelial cells and angiogenesis by 3,3'-diindolylmethane Carcinogenesis, March 1, 2006; 27(3): 541 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dixelius, A.-K. Olsson, A. Thulin, C. Lee, I. Johansson, and L. Claesson-Welsh Minimal Active Domain and Mechanism of Action of the Angiogenesis Inhibitor Histidine-Rich Glycoprotein Cancer Res., February 15, 2006; 66(4): 2089 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bohman, T. Matsumoto, K. Suh, A. Dimberg, L. Jakobsson, S. Yuspa, and L. Claesson-Welsh Proteomic Analysis of Vascular Endothelial Growth Factor-induced Endothelial Cell Differentiation Reveals a Role for Chloride Intracellular Channel 4 (CLIC4) in Tubular Morphogenesis J. Biol. Chem., December 23, 2005; 280(51): 42397 - 42404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mukherjee, R. Bhattacharya, P. Wang, L. Wang, S. Basu, J. A. Nagy, A. Atala, D. Mukhopadhyay, and S. Soker Antiangiogenic Properties of Gold Nanoparticles Clin. Cancer Res., May 1, 2005; 11(9): 3530 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Lu and A. J. Schroit Vascularization of Melanoma by Mobilization and Remodeling of Preexisting Latent Vessels to Patency Cancer Res., February 1, 2005; 65(3): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Frantz, K. A. Vincent, O. Feron, and R. A. Kelly Innate Immunity and Angiogenesis Circ. Res., January 7, 2005; 96(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.S. RUDGE, G. THURSTON, S. DAVIS, N. PAPADOPOULOS, N. GALE, S.J. WIEGAND, and G.D. YANCOPOULOS VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGene(R)- based Discovery of the Next Generation of Angiogenesis Targets Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 411 - 418. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Castelli, F. Porro, and P. Tarsia The heparins and cancer: review of clinical trials and biological properties Vascular Medicine, August 1, 2004; 9(3): 205 - 213. [Abstract] [PDF]
|
|
|
|
|
|
D. W. Davis, K. Inoue, C. P. N. Dinney, D. J. Hicklin, J. L. Abbruzzese, and D. J. McConkey Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts Cancer Res., July 1, 2004; 64(13): 4601 - 4610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakajima, T. Gotanda, H. Uchimiya, T. Furukawa, M. Haraguchi, R. Ikeda, T. Sumizawa, H. Yoshida, and S.-i. Akiyama Inhibition of Metastasis of Tumor Cells Overexpressing Thymidine Phosphorylase by 2-Deoxy-L-Ribose Cancer Res., March 1, 2004; 64(5): 1794 - 1801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Hood, R. Frausto, W. B. Kiosses, M. A. Schwartz, and D. A. Cheresh Differential {alpha}v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis J. Cell Biol., September 1, 2003; 162(5): 933 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Dvorak How Tumors Make Bad Blood Vessels and Stroma Am. J. Pathol., June 1, 2003; 162(6): 1747 - 1757. [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Fu and S. Shen Structural mechanisms of acute VEGF effect on microvessel permeability Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2124 - H2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zeng, D. Zhao, S. Yang, K. Datta, and D. Mukhopadhyay Heterotrimeric G{alpha}q/G{alpha}11 Proteins Function Upstream of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (KDR) Phosphorylation in Vascular Permeability Factor/VEGF Signaling J. Biol. Chem., May 30, 2003; 278(23): 20738 - 20745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-H. Lee, H. K. Avraham, S. Jiang, and S. Avraham Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability J. Biol. Chem., February 7, 2003; 278(7): 5277 - 5284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Sheetz and G. L. King Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications JAMA, November 27, 2002; 288(20): 2579 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hetian, A. Ping, S. Shumei, L. Xiaoying, H. Luowen, W. Jian, M. Lin, L. Meisheng, Y. Junshan, and S. Chengchao A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor J. Biol. Chem., November 1, 2002; 277(45): 43137 - 43142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Rauniyar, K. Suzuma, A. L. King, L. P. Aiello, and G. L. King Differential Effects of Bactericidal/Permeability-Increasing Protein (BPI) Analogues on Retinal Neovascularization and Retinal Pericyte Growth Invest. Ophthalmol. Vis. Sci., February 1, 2002; 43(2): 503 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Matthies, Q. E. H. Low, M. W. Lingen, and L. A. DiPietro Neuropilin-1 Participates in Wound Angiogenesis Am. J. Pathol., January 1, 2002; 160(1): 289 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Epstein, R. Kornowski, S. Fuchs, and H. F. Dvorak Angiogenesis Therapy : Amidst the Hype, the Neglected Potential for Serious Side Effects Circulation, July 3, 2001; 104(1): 115 - 119. [Full Text] [PDF]
|
|
|
|
|
|
H. Ishihama, M. Ohbayashi, N. Kurosawa, T. Kitsukawa, O. Matsuura, Y. Miyake, and T. Muramatsu Colocalization of Neuropilin-1 and Flk-1 in Retinal Neovascularization in a Mouse Model of Retinopathy Invest. Ophthalmol. Vis. Sci., May 1, 2001; 42(6): 1172 - 1178. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Smorenburg and C. J. F. Van Noorden The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies Pharmacol. Rev., March 1, 2001; 53(1): 93 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schwesinger, C. Yee, R. M. Rohan, A. M. Joussen, A. Fernandez, T. N. Meyer, V. Poulaki, J. J. K. Ma, T. M. Redmond, S. Liu, et al. Intrachoroidal Neovascularization in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in the Retinal Pigment Epithelium Am. J. Pathol., March 1, 2001; 158(3): 1161 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour, and R. Kornowski Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc Res, February 16, 2001; 49(3): 532 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Collen, S. M. Smorenburg, E. Peters, F. Lupu, P. Koolwijk, C. Van Noorden, and V. W. M. van Hinsbergh Unfractionated and Low Molecular Weight Heparin Affect Fibrin Structure and Angiogenesis in Vitro Cancer Res., November 1, 2000; 60(21): 6196 - 6200. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Fischer, M. Wobben, J. Kleinstuck, D. Renz, and W. Schaper Effect of astroglial cells on hypoxia-induced permeability in PBMEC cells Am J Physiol Cell Physiol, October 1, 2000; 279(4): C935 - C944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shiose, T. Sakamoto, H. Yoshikawa, Y. Hata, Y. Kawano, T. Ishibashi, H. Inomata, K. Takayama, and H. Ueno Gene Transfer of a Soluble Receptor of VEGF Inhibits the Growth of Experimental Eyelid Malignant Melanoma Invest. Ophthalmol. Vis. Sci., August 1, 2000; 41(9): 2395 - 2403. [Abstract] [Full Text]
|
|
|
|
|
|
A. Ferrario, K. F. von Tiehl, N. Rucker, M. A. Schwarz, P. S. Gill, and C. J. Gomer Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma Cancer Res., August 1, 2000; 60(15): 4066 - 4069. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Liu, L. Liu, W. F. Anderson, R. W. Beart, E. M. Gordon, and F. L. Hall Incorporation of Tumor Vasculature Targeting Motifs into Moloney Murine Leukemia Virus Env Escort Proteins Enhances Retrovirus Binding and Transduction of Human Endothelial Cells J. Virol., June 1, 2000; 74(11): 5320 - 5328. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Stockhammer, W. Poewe, S. Burgstaller, F. Deisenhammer, A. Muigg, S. Kiechl, E. Schmutzhard, H. Maier, S. Felber, P. Schumacher, et al. Vascular endothelial growth factor in CSF: A biological marker for carcinomatous meningitis Neurology, April 25, 2000; 54(8): 1670 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Q. Guo, L.-W. Wu, J. D. Dunbar, O. N. Ozes, L. D. Mayo, K. M. Kessler, J. A. Gustin, M. R. Baerwald, E. A. Jaffe, R. S. Warren, et al. Tumor Necrosis Factor Employs a Protein-tyrosine Phosphatase to Inhibit Activation of KDR and Vascular Endothelial Cell Growth Factor-induced Endothelial Cell Proliferation J. Biol. Chem., April 6, 2000; 275(15): 11216 - 11221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Ellis, Y. Takahashi, W. Liu, and R. M. Shaheen Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications Oncologist, April 1, 2000; 5(90001): 11 - 15. [Abstract] [Full Text]
|
|
|
|
|
|
H.M.W. Verheul, K. Hoekman, A.S. Jorna, E.F. Smit, and H.M. Pinedo Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion Formation Oncologist, April 1, 2000; 5(90001): 45 - 50. [Abstract] [Full Text]
|
|
|
|
|
|
L.-W. Wu, L. D. Mayo, J. D. Dunbar, K. M. Kessler, M. R. Baerwald, E. A. Jaffe, D. Wang, R. S. Warren, and D. B. Donner Utilization of Distinct Signaling Pathways by Receptors for Vascular Endothelial Cell Growth Factor and Other Mitogens in the Induction of Endothelial Cell Proliferation J. Biol. Chem., February 18, 2000; 275(7): 5096 - 5103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, et al. Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors Cancer Res., October 1, 1999; 59(20): 5209 - 5218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Oh, H. Takagi, C. Takagi, K. Suzuma, A. Otani, K. Ishida, M. Matsumura, Y. Ogura, and Y. Honda The Potential Angiogenic Role of Macrophages in the Formation of Choroidal Neovascular Membranes Invest. Ophthalmol. Vis. Sci., August 1, 1999; 40(9): 1891 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Thakker, D. P. Hajjar, W. A. Muller, and T. K. Rosengart The Role of Phosphatidylinositol 3-Kinase in Vascular Endothelial Growth Factor Signaling J. Biol. Chem., April 9, 1999; 274(15): 10002 - 10007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fischer, M. Clauss, M. Wiesnet, D. Renz, W. Schaper, and G. F. Karliczek Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO Am J Physiol Cell Physiol, April 1, 1999; 276(4): C812 - C820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Hayes, L Y Li, and M E Lippman Science, medicine, and the future: Antivascular therapy: a new approach to cancer treatment BMJ, March 27, 1999; 318(7187): 853 - 856. [Full Text]
|
|
|
|
|
|
C. Metais, J. Li, J. Li, M. Simons, and F. W. Sellke Effects of coronary artery disease on expression and microvascular response to VEGF Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1411 - H1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mesiano, N. Ferrara, and R. B. Jaffe Role of Vascular Endothelial Growth Factor in Ovarian Cancer : Inhibition of Ascites Formation by Immunoneutralization Am. J. Pathol., October 1, 1998; 153(4): 1249 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ruckman, L. S. Green, J. Beeson, S. Waugh, W. L. Gillette, D. D. Henninger, L. Claesson-Welsh, and N. Janjic 2'-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165). INHIBITION OF RECEPTOR BINDING AND VEGF-INDUCED VASCULAR PERMEABILITY THROUGH INTERACTIONS REQUIRING THE EXON 7-ENCODED DOMAIN J. Biol. Chem., August 7, 1998; 273(32): 20556 - 20567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hata, E. Duh, K. Zhang, G. S. Robinson, and L. P. Aiello Transcription Factors Sp1 and Sp3 Alter Vascular Endothelial Growth Factor Receptor Expression through a Novel Recognition Sequence J. Biol. Chem., July 24, 1998; 273(30): 19294 - 19303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Kevil, D. K. Payne, E. Mire, and J. S. Alexander Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins J. Biol. Chem., June 12, 1998; 273(24): 15099 - 15103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yang, S. Bunting, A. Ko, B. A. Keyt, N. B. Modi, T. F. Zioncheck, N. Ferrara, and H. Jin Substantially Attenuated Hemodynamic Responses to Escherichia coli-Derived Vascular Endothelial Growth Factor Given by Intravenous Infusion Compared with Bolus Injection J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 103 - 110. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. M. Höper, N. F. Voelkel, T. O. Bates, J. D. Allard, M. Horan, D. Shepherd, and R. M. Tuder Prostaglandins Induce Vascular Endothelial Growth Factor in a Human Monocytic Cell Line and Rat Lungs via cAMP Am. J. Respir. Cell Mol. Biol., December 1, 1997; 17(6): 748 - 756. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Y. Cheung Vascular Endothelial Growth Factor: Possible Role in Fetal Development and Placental Function Reproductive Sciences, July 1, 1997; 4(4): 169 - 177. [Abstract] [PDF]
|
|
|
|
 |
|
 R. O SCHLINGEMANN and V. W M VAN HINSBERGH Role of vascular permeability factor/vascular endothelial growth factor in eye disease Br. J. Ophthalmol., June 1, 1997; 81(6): 501 - 512. [Full Text] [PDF]
|
